Bluejay Diagnostics, Inc. entered into a Distribution, Co-Marketing & Strategic Partnership Agreement with Lovell Government Services, Inc., an SDVOSB specializing in federal healthcare distribution. The agreement grants Lovell exclusive rights to distribute Bluejay’s medical diagnostic products for federal procurement opportunities requiring or favoring SDVOSB set-aside status, including those within the Department of Veterans Affairs, Department of Defense, and Indian Health Service. Lovell holds non-exclusive rights for open-market government procurements. Under the terms, Lovell receives an approximate 15% distribution fee on gross sales through federal catalogs, with a 2% fee allocated for DAPA prime vendor sales. Bluejay paid a one-time establishment fee of $5,500. The partnership has an initial two-year term and is contingent upon FDA clearance or other regulatory authorization for the products. Bluejay Diagnostics operates in the medical diagnostics industry, developing near-patient testing systems for sepsis triage.

Bluejay Diagnostics reported Q2 2026 results, highlighting the completion of targeted enrollment for its SYMON-II pivotal clinical study involving 750 patients and the advancement toward an FDA 510(k) submission. The company strengthened its balance sheet with approximately $9.6 million in cash at June 30, 2026, up from $5.2 million at year-end 2025, following a private placement in June that generated roughly $7.6 million in net proceeds. Management stated these resources are sufficient to fund operations through the second quarter of 2027 and noted the signing of a US manufacturing contract to mitigate supply-chain risks for its Symphony IL-6 test. Bluejay Diagnostics is a medical diagnostics company focused on developing rapid, near-patient testing systems for sepsis triage and monitoring.

On July 21, 2026, Bluejay Diagnostics announced the completion of patient enrollment for its SYMON-II multicenter clinical validation study ahead of schedule. The study enrolled 750 patients to evaluate the Symphony IL-6 test's ability to assess 28-day all-cause mortality risk in sepsis patients admitted to the ICU. Preliminary observations show an approximately 17% 28-day mortality rate. The company intends to use the resulting clinical dataset to support future FDA 510(k) regulatory submissions and commercialization of the Symphony platform. The company operates in the medical diagnostics industry, developing rapid, near-patient diagnostic technologies for critical care.

Bluejay Diagnostics, Inc. stockholders at the June 9, 2026 annual meeting approved an amendment to the 2021 Stock Plan to increase the number of shares reserved for issuance by 600,000. Stockholders also approved an amendment to the certificate of incorporation to authorize a reverse stock split of between 1-for-2 and 1-for-20, with the board of directors to determine the final ratio and timing (no later than June 9, 2027) at its discretion. Bluejay Diagnostics, Inc. is a diagnostics company.

Bluejay Diagnostics, Inc. closed a private placement of pre-funded warrants, Series G warrants, and Series H warrants, receiving approximately $7.7 million in proceeds. The securities were sold at a combined price of $2.324 per warrant package.